Vor Bio is working on a new platform for treating and curing blood cancers.
Combining expertise in Hematopoietic Stem Cell (HSC) biology, genome engineering, and the development of Chimeric Antigen Receptor T (CAR-T) cell therapies, we will realize our vision of a cure only with the help of first-class external partners.
Every year, thousands of patients with AML/MDS relapse post-transplant with no safe and effective treatment options. Vor Bio’s approach of shielded transplants provides the first opportunity to deliver potentially curative treatments post-transplant.
Based upon a deep understanding of HSC biology and using recent advances in genome engineering, we are editing HSCs to shield them from the damaging effects of targeted therapies post-transplant. This potentially allows treatment with powerful targeted therapies such as ADCs and CAR-Ts soon after transplant. Our clinical data has demonstrated that our approach has the potential to protect patients’ healthy cells, as all patients who have received a shielded transplant and have been treated with Mylotarg have demonstrated durable hematologic protection from deep cypotenias through repeat doses.